Sarcoma
![Promising Objective Response Rate (ORR) Observed in Phase II Trial of Envafolimab for Sarcoma](https://pharmtales.com/wp-content/uploads/2023/06/Promising-Objective-Response-Rate-ORR-Observed-in-Phase-II-Trial-of-Envafolimab-for-Sarcoma.jpg)
Promising Objective Response Rate (ORR) Observed in Phase II Trial of Envafolimab for Sarcoma
SG Tylor
Source: TRACON Pharmaceuticals Positive findings from the ongoing Phase II ENVASARC trial (NCT04480502) demonstrate that envafolimab (KN035), either as a ...